Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies

ROR1 CAR-T cells were well tolerated in most patients. Antitumor activity was observed in CLL but was limited in TNBC and NSCLC. Immunogenicity of the CAR and lack of sustained tumor infiltration were identified as limitations. See related commentary by Kobold, p. 437.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-10-28
DOI
https://doi.org/10.1158/1078-0432.ccr-24-2172
Citations
31
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
8.76

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies

David G. Maloney, Jennifer M. Specht, Brandon Seaton, Hugh Macmillan et al.
31 citations
Clinical Cancer Research
CAR-T cell therapy research
8.76
article

Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies

David G. Maloney, Jennifer M. Specht, Brandon Seaton, Hugh Macmillan, Qian Wu, Lauri D. Aicher, Gabriel O. Cole, Shalini Pullarkat, Jenna Voutsinas, Evan W. Newell, Cecilia C.S. Yeung, Yun Lo, Sylvia M. Lee, Carla A. Jaeger-Ruckstuhl, Robert H. Pierce, Stanley R. Riddell, Vishaka Muhunthan, Xiaoling Song, Jocelyn H. Wright, Carolina Berger, Teresa S. Hyun
article en
31 citations

Abstract

ROR1 CAR-T cells were well tolerated in most patients. Antitumor activity was observed in CLL but was limited in TNBC and NSCLC. Immunogenicity of the CAR and lack of sustained tumor infiltration were identified as limitations. See related commentary by Kobold, p. 437.

Clinical Cancer ResearchVol. 31(3)
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), University of Washington (US), University of Washington Medical Center (US), Fred Hutch Cancer Center (US), University of Washington Applied Physics Laboratory (US)
American Cancer Society, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 1%
CAR-T cell therapy research
8.76
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.